

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**REQUEST FOR ACCESS TO AN ABANDONED APPLICATION UNDER 37 CFR 1.14**Bring completed form to:  
File Information Unit, Room 2E04  
2900 Crystal Drive  
Arlington, VA 22202-3514

Telephone: (703) 308-2733

In re Application of

Application Number

08162,407

Filed

12/3/93

Paper No. #14

I hereby request access under 37 CFR 1.14(a)(1)(iv) to the application file record of the above-identified **ABANDONED** application, which is not within the file jacket of a pending Continued Prosecution Application (CPA) (37 CFR 1.53(d)) and which is identified in, or to which a benefit is claimed, in the following document (as shown in the attachment):

United States Patent Application Publication No. \_\_\_\_\_, page, \_\_\_\_\_ line \_\_\_\_\_,

United States Patent Number 5554502, column \_\_\_\_\_, line, \_\_\_\_\_ or

WIPO Pub. No. \_\_\_\_\_, page \_\_\_\_\_, line \_\_\_\_\_.

**Related Information About Access to Applications Maintained in the Image File Wrapper System (IFW) and Access to Pending Applications in General**

A member of the public, acting without a power to inspect, cannot order applications maintained in the IFW system through the FIU. If the member of the public is entitled to a copy of the application file, then the file is made available through the Public Patent Application Information Retrieval system (Public PAIR) on the USPTO internet web site ([www.uspto.gov](http://www.uspto.gov)). Terminals that allow access to Public PAIR are available in the Public Search Room. The member of the public may also be entitled to obtain a copy of all or part of the application file upon payment of the appropriate fee. Such copies must be purchased through the Office of Public Records upon payment of the appropriate fee (37 CFR 1.19(b)).

For **published** applications that are still pending, a member of the public may obtain a copy of:

the file contents; the pending application as originally filed; or any document in the file of the pending application.

For **unpublished** applications that are still pending:

- (1) If the benefit of the pending application is claimed under 35 U.S.C. 119(e), 120, 121, or 365 in another application that has: (a) issued as a U.S. patent, or (b) published as a statutory invention registration, a U.S. patent application publication, or an international patent application publication in accordance with PCT Article 21(2), a member of the public may obtain a copy of: the file contents; the pending application as originally filed; or any document in the file of the pending application.
- (2) If the application is incorporated by reference or otherwise identified in a U.S. patent, a statutory invention registration, a U.S. patent application publication, or an international patent application publication in accordance with PCT Article 21(2), a member of the public may obtain a copy of the pending application as originally filed.

*Aziz Copy*

Signature

*Aziz Tesfay*

Typed or printed name

4/29/08

Date

Registration Number, if applicable

703-486-1150

Telephone Number

FOR PTO USE ONLY

RECEIVED

Approved by:

APR 29 2008

(initials)

Unit:

File Information Unit

This collection of information is required by 37 CFR 1.11 and 1.14. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. BRING TO: File Information Unit, Room 2E04, 2900 Crystal Drive, Arlington, Virginia.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



US005554512A

#14

**United States Patent** [19][11] **Patent Number:** **5,554,512****Lyman et al.**[45] **Date of Patent:** **Sep. 10, 1996**[54] **LIGANDS FOR FLT3 RECEPTORS**[75] **Inventors:** **Stewart D. Lyman, Seattle; M.  
Patricia Beckmann, Poulsbo, both of  
Wash.**[73] **Assignee:** **Immunex Corporation**[21] **Appl. No.:** **243,545**[22] **Filed:** **May 11, 1994****Related U.S. Application Data**[63] Continuation-in-part of Ser. No. 209,502, Mar. 7, 1994,  
abandoned, which is a continuation-in-part of Ser. No.  
162,407, Dec. 3, 1993, abandoned, which is a continuation-  
in-part of Ser. No. 111,758, Aug. 25, 1993, abandoned,  
which is a continuation-in-part of Ser. No. 106,463, Aug. 12,  
1993, abandoned, which is a continuation-in-part of Ser. No.  
68,394, May 24, 1993, abandoned.[51] **Int. Cl.<sup>6</sup>** ..... **C12N 15/19; C07H 21/04**[52] **U.S. Cl.** ..... **435/69.5; 435/69.1; 435/172.1;  
435/240.2; 435/252.3; 435/320.1; 530/351;  
530/399; 536/23.5; 935/13; 424/85.1**[58] **Field of Search** ..... **536/23.5; 530/350,  
530/351, 399; 435/69.1, 69.5, 69, 7, 240.2,  
320.1, 172.1, 252.3; 935/13; 424/85.1**

[56]

**References Cited****U.S. PATENT DOCUMENTS**

5,185,438 2/1993 Lemischka ..... 536/23.2

**OTHER PUBLICATIONS**

J. G. Flanagan et al. Cell 63:185-194, 1990.

O. Rosnet et al. Oncogene 6:1641-1650, Sep. 1991.

*Primary Examiner*—Stephen G. Walsh*Assistant Examiner*—Lorraine M. Spector*Attorney, Agent, or Firm*—Stephen L. Malaska

[57]

**ABSTRACT**

Ligands for flt3 receptors capable of transducing self-renewal signals to regulate the growth, proliferation or differentiation of progenitor cells and stem cells are disclosed. The invention is directed to flt3-L as an isolated protein, the DNA encoding the flt3-L, host cells transfected with cDNAs encoding flt3-L, compositions comprising flt3-L, methods of improving gene transfer to a mammal using flt3-L, and methods of improving transplantations using flt3-L. Flt3-L finds use in treating patients with anemia, AIDS and various cancers.

**21 Claims, No Drawings**